Top sclc Articles in Oncology

Radiochemotherapy in small-cell lung cancer
Expert Review of Anticancer Therapy, 10/20/2009

cell lung cancer (SCLC). The PCI in extensive–disease SCLC improves survival at the expense of worsening of short–term health–related quality of life. There is evidence that consolidation thoracic radiotherapy may be of value in extensive–disease SCLC. The recently initiated [more...]

New Advances in the Second-Line Treatment of Small Cell Lung Cancer
The Oncologist, 10/28/2009

Hurwitz JL et al. – SCLC overexpresses antiapoptotic members of the Bcl–2 family in ~80% of cases. Several Bcl–2 inhibitors, including obatoclax, are currently entering clinical trials in SCLC and are an exciting area of drug development in the relapsed [more...]

Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer
Journal of Clinical Oncology, 10/29/2009

in patients with extensive-stage disease, small-cell lung cancer.The addition of bevacizumab to cisplatin and etoposide in patients with ED-SCLC results in improved PFS and OS relative to historical controls who received this chemotherapy regimen without bevacizumab. This regimen appears to be well [more...]

Screening the Drug Sensitivity Genes Related to GEM and CDDP in the Lung Cancer Cell-lines
Chinese Journal of Lung Cancer, 10/20/2009

Yang C et al. – There existed drug–related sensitive genes of GEM, CDDP in SCLC and NSCLC cell lines; of these genes, Metallothinein, Cathepsin B and TIMP1 genes presented a significant positive correlation with GEM drug sensitivity [more...]

Differentially expressed micrornas in small cell lung cancer
Experimental Lung Research, 10/21/2009

Miko E et al. – The aberrant miRNA profile of SCLC may offer new insights in the biology of this aggressive tumor, and could potentially provide novel diagnostic markers. [more...]

Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501
Journal of Clinical Oncology, 10/15/2009

Horn L et al. – The addition of bevacizumab to cisplatin and etoposide in patients with ED-SCLC results in improved PFS and OS relative to historical controls who received this chemotherapy regimen without bevacizumab. This regimen appears to [more...]

Dermatomyositis and small cell carcinoma of the bladder
Canadian Family Physician, 10/14/2009

carcinoma of the bladder (SCCB) and dermatomyositis (DM). The lack of previous such observations, as opposed to an abundance of reports connecting SCLC and DM, presumably stems from the rarity of the former tumour as opposed to the preponderance of lung carcinoma. [more...]

A phase II study of amrubicin combined with carboplatin for elderly patients with small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0405
Annals of Oncology, 10/20/2009

Inoue A et al. – Amrubicin combined with carboplatin is quite effective for SCLC with acceptable toxic effects even for the elderly population. Further evaluation of this regimen is warranted. [more...]

Oestrogen plus progestin and lung cancer in postmenopausal women (Womens Health Initiative trial): a post-hoc analysis of a randomised controlled trial
The Lancet, 10/12/2009

plus 2·5 mg medroxyprogesterone acetate (n=8506) or matching placebo (n=8102) Assessed incidence and mortality rates for all lung cancer, SCLC, and NSCLC by use of data from treatment and post-intervention follow-up periods Analysis was by intention to treat Results ... higher number of deaths from NSCLC in combined therapy group (62 vs 31 deaths; 0·09% vs 0·05%; HR 1·87, 1·22—2·88) Incidence and mortality rates of SCLC similar between groups [more...]

Etoposide plus cisplatin followed by concurrent chemo-radiotherapy and irinotecan plus cisplatin for patients with limited-stage small cell lung cancer: A multicenter phase II study
Lung Cancer, 10/05/2009

Xenidis N et al. – Consolidation chemotherapy with IP following concurrent EP plus TRT is a safe and with acceptable toxicity regimen and deserves further phase III testing in patients with LS–SCLC. [more...]